肺がんスクリーニング市場規模、シェア、成長分析：がんタイプ別、診断タイプ別、エンドユーザー別、地域別 - 産業予測 2025年～2032年

肺がんスクリーニングの世界市場規模は2023年に35億米ドルと評価され、2024年の38億2,000万米ドルから2032年には76億6,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは9.1％で成長する見通しです。

世界の肺がんスクリーニング市場は、スクリーニング技術の進歩やタバコの使用率の上昇に後押しされ、大きな成長が見込まれています。2021年には約255万人の学生がタバコ製品を摂取していると報告されており、2020年時点では米国成人の約13％がタバコを喫煙していることから、肺がん罹患率の増加により効果的なスクリーニングソリューションの需要が高まっています。低線量コンピュータ断層撮影（CT）は、特にインドや中国のような発展途上国で、革新的なスクリーニング技術に対する認識が高まっており、医療従事者の間で人気を集めています。また、啓発プログラムの提携など、協力的な取り組みも生まれています。しかし、高額な検診費用や放射線被曝への懸念は、顕著な課題となっています。市場の持続的成長には、技術の進歩と一般市民への教育を通じてこれらの問題に対処することが不可欠です。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 技術の進歩
• 規制情勢
• 特許分析

肺がんスクリーニング市場規模：がんタイプ別& CAGR（2025-2032）

• 市場概要
• 非小細胞肺がん（NSCLC）
• 小細胞肺がん

肺がんスクリーニング市場規模：診断タイプ別& CAGR（2025-2032）

• 市場概要
• 低線量スパイラルCTスキャン
• 胸部X線

肺がんスクリーニング市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院・クリニック
• 診断センター

肺がんスクリーニング市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• General Electric Company（USA）
• Koninklijke Philips N.V.（Netherlands）
• Siemens Healthineers（Germany）
• Canon Medical Systems Corporation（Japan）
• FUJIFILM Holdings Corporation（Japan）
• Medtronic（USA）
• Nuance Communications, Inc.（USA）
• Eon（USA）
• Volpara Health Limited（New Zealand）
• Hitachi, Ltd.（Japan）
• Toshiba Corporation（Japan）
• Hologic, Inc.（USA）
• Agfa-Gevaert Group（Belgium）
• Carestream Health（USA）
• Mindray Medical International Limited（China）
• Esaote S.p.A.（Italy）
• Shimadzu Corporation（Japan）
• ViewRay, Inc.（USA）

結論と推奨事項

Global Lung Cancer Screening Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 3.82 billion in 2024 to USD 7.66 billion by 2032, growing at a CAGR of 9.1% during the forecast period (2025-2032).

The global lung cancer screening market is poised for significant growth, fueled by advancements in screening technologies and the rising prevalence of tobacco use. With approximately 2.55 million students reportedly consuming tobacco products in 2021 and nearly 13% of U.S. adults smoking cigarettes as of 2020, the increasing incidence of lung cancer heightens the demand for effective screening solutions. Low-dose computed tomography (CT) is gaining traction among healthcare professionals, particularly in developing countries like India and China, where awareness of innovative screening techniques is on the rise. Collaborative initiatives, such as partnerships for awareness programs, have also emerged. However, high screening costs and concerns about radiation exposure present notable challenges. Addressing these issues through technological advancements and public education will be vital for sustained market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Screening Market Segments Analysis

Global Lung Cancer Screening Market is segmented by Cancer Type, Diagnosis Type, End-user and region. Based on Cancer Type, the market is segmented into Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer. Based on Diagnosis Type, the market is segmented into Low Dose Spiral CT Scan and Chest X-ray. Based on End-user, the market is segmented into Hospitals & Clinics and Diagnostic Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Screening Market

The Global Lung Cancer Screening market is significantly propelled by the alarming rise in lung cancer cases, which continues to be one of the foremost causes of cancer-related fatalities across the globe. This increasing prevalence, particularly in developing nations, highlights an urgent need for effective early detection methods. Consequently, there is a growing impetus for the implementation of screening programs aimed at identifying lung cancer at its initial stages. As awareness of lung cancer's impact rises, healthcare systems are increasingly prioritizing screening initiatives, thereby fostering the expansion and development of the lung cancer screening market on a global scale.

Restraints in the Global Lung Cancer Screening Market

The Global Lung Cancer Screening market faces several challenges, particularly associated with the use of Low-Dose Computed Tomography (LDCT) screenings. These screenings can sometimes yield false-positive results, necessitating further tests and creating unwarranted anxiety for patients. Additionally, these unnecessary investigations can incur extra costs and may even expose patients to complications arising from unnecessary procedures. Another concern is the issue of overdiagnosis, where patients are identified with lung nodules that are unlikely to cause harm. This situation can result in overtreatment and invasive interventions, complicating the overall management of patients and negatively impacting their quality of life.

Market Trends of the Global Lung Cancer Screening Market

The Global Lung Cancer Screening market is increasingly moving towards personalized screening approaches, reflecting a significant trend characterized by the customization of screening strategies based on individual risk factors such as smoking history, occupational exposures, and genetic predispositions. By implementing risk stratification algorithms, healthcare providers can identify high-risk populations more effectively, thereby optimizing resource allocation and enhancing the overall efficacy of screening interventions. This shift not only improves early detection rates but also aligns with the broader healthcare movement towards precision medicine, ultimately driving market growth as stakeholders invest in technologies and solutions that cater to diverse patient profiles and enhance healthcare outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Advancement
• Regulatory Landscape
• Patent Analysis

Global Lung Cancer Screening Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer

Global Lung Cancer Screening Market Size by Diagnosis Type & CAGR (2025-2032)

• Market Overview
• Low Dose Spiral CT Scan
• Chest X-ray

Global Lung Cancer Screening Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers

Global Lung Cancer Screening Market Size & CAGR (2025-2032)

• North America (Cancer Type, Diagnosis Type, End-user)
  • US
  • Canada
• Europe (Cancer Type, Diagnosis Type, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Diagnosis Type, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Diagnosis Type, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Diagnosis Type, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• General Electric Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nuance Communications, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eon (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Volpara Health Limited (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi, Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Toshiba Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agfa-Gevaert Group (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carestream Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mindray Medical International Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Esaote S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shimadzu Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViewRay, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations